Astria Therapeutics, Inc.

Astria Therapeutics, Inc.

ATXS·NASDAQ

$12.58

+0.0000%
HealthcareBiotechnology

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

At a Glance

Live Snapshot
Market Cap$718.13M
EPS-1.6800
P/E Ratio-7.49
Earnings Date03/10/2026

atxs

Investments in Property, Plant, and Equipment

Last Annual Value

-325.00K

3-Year CAGR

-149%

5-Year CAGR

-93%

10-Year CAGR

-4%

Astria Therapeutics, Inc.

Astria Therapeutics, Inc. Competitors Analysis of Investments in Property, Plant, and Equipment

ATXS · NASDAQ
CompanyInvestments in Property, Plant, and Equipment
CAGR 3Y
CAGR 5Y
CAGR 10Y
-325.00K
N/AN/AN/A 
-33.84M
N/AN/AN/A
ERAS logo
Erasca, Inc.
NASDAQ:ERAS
-128.00K
N/AN/AN/A
0.00
N/AN/AN/A
-1.93M
N/AN/AN/A
-6.69M
N/AN/AN/A
ARVN logo
Arvinas, Inc.
NASDAQ:ARVN
-1.90M
N/AN/AN/A
-320.00K
N/AN/AN/A
-7.67M
N/AN/AN/A
-3.83M
N/AN/AN/A
Astria Therapeutics, Inc.

Astria Therapeutics, Inc. Fair Value Envelope

ATXS · NASDAQ

Our analysis suggests that ATXS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $12.58, this represents a potential HIDDEN relative to our calculated worth for Astria Therapeutics, Inc..

Intrinsic Value
Current Price: $12.58